Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis
NCT06521762Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of etrasimod in immune checkpoint inhibitor-induced colitis, sponsored by Yale University. Planned start Jan 2026; status: withdrawn.
02
Drugs
etrasimod
03
Conditions
immune checkpoint inhibitor-induced colitis
Beyond the preview
Go deeper on NCT06521762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06521762.